FDA Oks Novo Weekly Diabetes Injection

Dec 07, 2017

The FDA has approved Novo Nordisk’s Ozempic, a once-weekly injection for type 2 diabetes.

Ozempic consists of a weekly injection of semaglutide, which belongs to a type of drugs known as glucagon-like peptide 1 (GLP-1) receptor agonists.

In October, an FDA panel had voted unanimously in favor of the treatment. Trials included favorable head-to-head data against Eli Lilly’s rival drug, Trulicity, which is already on the market.

Analysts, using Thomson Reuters data, expect annual Ozempic, sales to reach $3.17 billion by 2023, with sales of Trulicity, rising to $3.71 billion.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments